Skip Nav Destination
1-15 of 15
Biochem Soc Trans (2022) 50 (6): 1897–1909.
Published: 09 December 2022
... maintenance. miRs as therapeutic reagents in tissue regeneration and repair hold great promise and new technologies are currently being designed to facilitate their expression or inhibition. Due to the large amount of miR research in cells and cancer many cellular processes and gene networks have been...
Biochem Soc Trans (2022) 50 (6): 1823–1836.
Published: 01 December 2022
... may open up novel therapeutic options for targeting discrete oncogenic JNK signaling complexes in specific cancer settings. In terms of protein structure, JNKs comprise distinct N- and C-terminal lobes that are linked by a flexible hinge loop ( Figure 2A ). This hinge loop and the structural...
Biochem Soc Trans (2021) 49 (3): 1385–1395.
Published: 01 June 2021
... to be considered as therapeutic targets. In the past two decades, around 45 drugs targeting chemokine receptors have been developed, yet only three are clinically approved. The challenging factors include the limited understanding of aberrant chemokine signalling in malignant diseases, high redundancy...
Biochem Soc Trans (2020) 48 (5): 2079–2088.
Published: 01 September 2020
...Thanh Kha Phan; Dilara Ceyda Ozkocak; Ivan Ka Ho Poon Extracellular vesicles (EVs), membrane-bound vesicles that are naturally released by cells, have emerged as new therapeutic opportunities. EVs, particularly exosomes and microvesicles, can transfer effector molecules and elicit potent responses...
Biochem Soc Trans (2020) 48 (3): 1269–1285.
Published: 08 June 2020
... The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 2020 BMP9 crosstalk non-coding rna osteogenesis therapeutics Oral and maxillofacial surgery often aims for both functional and esthetic outcomes, both of which are mostly dependent on the underlying...
Biochem Soc Trans (2019) 47 (5): 1209–1222.
Published: 10 September 2019
... and it has been demonstrated that disruption of some of these proteins can cause cancer-specific inhibition of cell growth. For certain targets therapeutically relevant interventions are being investigated, for example, small molecule inhibitors, although none are yet in clinical trials. As the field is now...
Biochem Soc Trans (2018) 46 (4): 891–909.
Published: 19 July 2018
...Ruby Macdonald; Katy Barnes; Christopher Hastings; Heather Mortiboys Mitochondrial abnormalities have been identified as a central mechanism in multiple neurodegenerative diseases and, therefore, the mitochondria have been explored as a therapeutic target. This review will focus on the evidence...
Biochem Soc Trans (2017) 45 (1): 101–112.
Published: 15 February 2017
... neurodegenerative disorders and, hopefully, offer the clinicians a toolbox of therapeutics to tailor the most effective or personalized treatments for individual patients. An intriguing aspect of many neurodegenerative disorders, such as AD, PD, ALS and HD, is that even though they arise from mutations...
Biochem Soc Trans (2017) 45 (1): 79–88.
Published: 15 February 2017
...Galina Semenova; Jonathan Chernoff p21-Activated kinase 1 (PAK1) has attracted much attention as a potential therapeutic target due to its central role in many oncogenic signaling pathways, its frequent dysregulation in cancers and neurological disorders, and its tractability as a target for small...
Biochem Soc Trans (2016) 44 (5): 1483–1490.
Published: 19 October 2016
...Carlo Viscomi Mitochondrial disorders are a group of genetic diseases affecting the energy-converting process of oxidative phosphorylation. The extreme variability of symptoms, organ involvement, and clinical course represent a challenge to the development of effective therapeutic interventions...
Biochem Soc Trans (2015) 43 (4): 593–594.
Published: 03 August 2015
... therapeutics TSPO In search of the mechanisms underlying human and animal physiopathology, it is a necessity to comprehend how body, tissues and cells adapt to continuous stimuli coming from the environment [ 1 ]. Whether these are physical, psychosocial or chemical adaptation to these stressors...
Biochem Soc Trans (2010) 38 (2): 507–510.
Published: 22 March 2010
... circuits during early development. In this case, therapeutic intervention during early development, perhaps before birth, may be required for effective treatment. A better understanding of these different roles will be fundamental not only for establishing new targets for Fragile X interventions, but also...
Biochem Soc Trans (2007) 35 (4): 767–769.
Published: 20 July 2007
... research and, as witnessed in 2007, candidate and emerging therapeutics. Thus it is anticipated that the further refinement of CPP technologies will provide drug-delivery vectors, cellular imaging tools, nanoparticulate devices and molecular therapeutics that will have a positive impact on the healthcare...
Biochem Soc Trans (2007) 35 (1): 1–6.
Published: 22 January 2007
... 2007 The Biochemical Society 2007 diagnostics epidermal growth factor receptor (EGFR) growth factor signalling therapeutics This short review describes the work that I have been doing for the last 45 years on growth factors, their receptors and signal transduction mechanisms. When I...
D. Zelent, H. Najafi, S. Odili, C. Buettger, H. Weik-Collins, C. Li, N. Doliba, J. Grimsby, F.M. Matschinsky
Biochem Soc Trans (2005) 33 (1): 306–310.
Published: 01 February 2005
...’. The case of GK research illustrates how basic science may culminate in therapeutic advances of human medicine. drug discovery genetics glucose glucokinase glucose homeostasis therapeutics 1 To whom correspondence should be addressed (email firstname.lastname@example.org ). 2 9...